Experts offer a solid endorsement for AcelRx pain med, spurring a big rally for their stock
The FDA forced AcelRx Pharmaceuticals to go back to the drawing board to refashion a better safety plan for its new pain therapy Dsuvia (ARX-04). And that paid off Friday with a big endorsement from the outside experts the agency drew together to review their marketing application.
The group voted a lopsided 10-3 in favor of a green light, as these experts were able to look past regulatory concerns about the potential for abuse and accidental exposure posed by the 30 mcg sufentanil tablets.
Unlock this article instantly by becoming a free subscriber.
You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.
